2
Sep
2025
Corsera Health, Led by Maraganore and Meanwell, Aims to Prevent Heart Disease
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
May
2023
Creating a New Class of Medicines: John Maraganore on The Long Run
Today’s guest on The Long Run is John Maraganore. John is best known as the former CEO of Alnylam Pharmaceuticals, the RNA interference drug developer. He spent 19 years there as CEO, before stepping down at the end of 2021. Alnylam figured out how to make a new therapeutic modality — gene-silencing with double-stranded oligonucleotide therapies. Alnylam’s technology has now... Read More
10
Apr
2023
In Support of FDA’s Authority to Regulate Medicines
On Friday, April 7, a federal judge with no scientific training fundamentally undermined the bipartisan authority granted by Congress to the Food and Drug Administration to approve and regulate safe, effective medicines for every American. District Judge Matthew Kacsmaryk issued a decision that overturns the FDA’s 23-year-old approval of mifepristone, the primary medicine used in abortion and miscarriage care, and... Read More
6
Mar
2023
Remote/Hybrid Work is Here to Stay. Biotech Should Embrace It
There has been much debate about the biotech workplace in the aftermath of pandemic disruptions. Employers and employees are all thinking about how and to what extent companies should enable and support remote-based work. People are discussing the advantages and disadvantages of remote work, especially in terms of the effect on productivity and creativity. This matters in biotech. The goal... Read More
24
Jan
2023
Biotech Needs to Get Back to Work in Person. Now.
Companies at the frontiers of science and medicine, developing new therapies for patients, are working on one of the most challenging endeavors known to humanity. Most would agree it’s more difficult than putting a man on the moon. The pandemic created a dramatic disruption to our globally networked economy. It will have far-ranging and long-lasting repercussions. It started with quarantine.... Read More
20
Jul
2020
Barring Foreign Talent Is An Assault on Biotech Innovation
As a first generation American (John Maraganore) and a proud immigrant (Jeremy Levin), we’re appalled by the relentless, short-sighted assaults by this Administration on legal immigration. The latest attempt specifically aims to limit, and potentially shut down, immigration to America of the world’s best and brightest minds. This is precisely the time we need these bright minds. Thankfully, in light... Read More
12
Feb
2015
Video: Alnylam’s John Maraganore and Canaan’s Julie Papanek at BIO CEO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.